R. Aquila - Vol. 10, December 2004, Issue 4
Testo Immagini Bibliografia Summary Indice
L’affidabilità di olanzapina nella
prevenzione delle ricadute della patologia schizofrenica
Reliability of olanzapine in preventing schizophrenic relapses
1 Lieberman JA, Alvir JM, Koreen A, Geisler S, Chakos M, Sheitman B, et al. Psychobiologic correlates of treatment response in schizophrenia. Neuropsychopharmacology 1996;14(3 Suppl):13s-21s.
2 Loebel AD, Lieberman JA, Alvir JM, Mayerhoff DI, Geisler SH, Szymanski SR. Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 1992;149:1183-8.
3 Larsen TK, Friis S, Haahr U, Joa I, Johannessen JO, Melle I, et al. Early detection and intervention in first-episode schizophrenia: a critical review. Acta Psychiatr Scand 2001;103:323-34.
4 Waddington JL, Youssef HA, Kinsella A. Sequential cross-selectional and 10-year prospective study of severe negative symptoms in relation of duration of initially untreated psychosis in chronic schizophrenia. Psychol Med 1995;25:849-57.
5 Mc Gorry PD, Edwards J, Mihalopoulos C, Harrigan SM, Jackson HJ. EPPIC. An envolving system of early detection and optimal management. Schizophr Bull 1996;22:305-26. Review.
6 Scully P, Coakley G, Kinsella A, Waddington J. Psychopatology, executive (frontal) and general cognitive impairment in relation to duration of initially untreated versus subsequently treated psychosis in chronic schizophrenia. Psychol Med 1997; 27:1303-1310.
7 Szymanski SR, Cannon TD, Gallacher F, Erwin RJ, Gur RE. Course and treatment response in first-episode and chronic schizophrenia. Am J Psychiatry 1996;153:519-25.
8 Wyatt RJ, Henter ID. The effects of early and sustained intervention on long term morbidity of schizophrenia. J Psychiatr Res 1998;32:169-77.
9 McGlashan TH, Johannessen JO. Early detection and intervention with schizophrenia: rationale. Schizophr Bull 1996;22:201-22.
10 Malla Ak, Norman RN, Cortese L, Cheng S, Diaz K, McIntosh E, et al. Symptoms and cognition as predictors of community functioning: a prospective analysis. Am J Psychiatry 1999;156:400-5.
11 McGorry PD,Yung AR. Early intervention in psychosis: an overdue reform. Aust N Z J Psychiatry 2003;37:393-8.
12 DeQuardo JR. Pharmacologic treatment of first-episode schizophrenia: early intervention is key to outcome. J Clin Psychiatry 1998;59(suppl 19):9-17.
13 Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second generation antipsychotics. Arch Gen Psychiatry 2003;60:553-64.
14 Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, et al. Comparative efficacy an safety of atypical and conventional antipsychotic drugs in first episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 2003;160:1396-404.
15 Tran PV, Tollefson GD, Sanger TM, Lu Y, Berg PH, Beasley CM Jr. Olanzapine versus haloperidol in the treatment of schizoaffective disorder. Acute and long-term therapy. Br J Psychiatry 1999;174:15-22.
16 Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457-65.
17 Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C Jr, et al. Double blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-18.
18 Aquila R, Weiden PJ, Kinon B, Zygmut A. Effectiveness of Olanzapine upon Psychiatric and Vocational Rehabilitation Outcomes. Poster presented at: 153th APA Annual Meeting 2000, Chicago, IL. USA.
19 Kollack-Walker S, Hill A, Liu H, Kinon BJ. Superiority of olanzapine versus quetiapine in improving overall functionig. 157th Annual Meeting APA 2004 May 1-6; New York, USA 2004.
20 Breier A, Roychowdhury SM. Comparison to Other Atypical Antipsychotics in Preventing Relapse in Patients with Schizophrenia. 42nd ACNP Annual Meeting Dec. 7-11, 2003 Puerto Rico.
21 Pigott TA. Poster presented at: 156th APA Annual Meeting: May 18-23 2002; Philadelphia PA. USA.
22 Beasley CM Jr, Sutton VK, Hamilton SH, Walker DJ, Dossenbach M, Taylor CC, et al. A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. J Clin Psychopharmacol 2003;23:582-94.
23 Corrigan PW, Liberman RP, Engel JD. From noncompliance to collaboration in the treatment of schizophrenia. Hosp Community Psychiatry 1990;41:1203-11.
24 Weiden PJ, Aquila R, Emanuel M, Zygmunt A. Long-term considerations after switching antipsychotics. J Clin Psychiatry 1998;59(suppl 19):36-49.
25 Kane JM, Berg PH, Thakore J, Naber D, Gattaz WF, Cavazzoni P, et al. Olanzapine versus ziprasidone: results of 28 week double-blind study in patients with schizophrenia. Poster presentation at the International Congress on Schizophrenia Research (ICOSR) meeting, March 2003 in Colorado Springs, Colo. J Psychopharmacol 2003; 17 (suppl 3): 50.
26 Jolley AG, Hirsch SR, Morrison E, McRink A, Wilson L. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. BMJ 1990;301(6756):837-42.
27 Carpenter WT Jr, Hanlon TE, Heinrichs DW, Summerfelt AT, Kirkpatrick B, Levine J, et al. Continous versus targeted medication in schizophrenic outpatients: outcome results. Am J Psychiatry 1990;147:1138-48.
28 Pietzcker A, Gaebel W, Kopcke W, Muller P, Bandelow B, Linden M, et al. Intermittent versus maintenance neuroleptic long-term treatment in schizophrenia - 2 years results of a German multicenter study. J Psychiatr Res 1993;27:321-39.
29 Cramer JA, Rosenheck R. Compliance with medication regims for mental and physical disorders. Psychiatr Serv 1998;49:196-201.
30 Aquila R, Weiden PJ, Emmanuel M. Compliance and the Rehabilitation Alliance. J Clin Psychiatry 1999;60 (suppl 19):23-7.
31 Naber D, Moritz S, Lambert M, Pajonk FG, Holzbach R, Mass R, et al. Improvement of schizophrenic patients subjective well-being under atypical antipsychotic drugs. Schizophr Res 2001;50:79-88.
32 Haro JM, Edgell ET, Jones PB, Alonso J, Gavart S, Gregor KJ, et al. The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment. Acta Psychiatr Scand 2003;107:222-32.
33 Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in the treatment of patient with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002;159:1018-28.
34 McCrory DJ. The rehabilitation alliance. J Voc Rehab 1991;1:58-66.
35 Weiden PJ, Havens L. Psychotherapeutic management techniques in the treatment of outpatients with schizophrenia. Hosp Community Psychiatry 1994;45:549-55.
36 Revicki DA, Genduso LA, Hamilton SH, Ganoczy D, Beasley CM Jr. Olanzapine vs haloperidol in the treatment of Schizophrenia and other psychotic disorders: quality of life and clinical outcomes of randomized clinical trials. Qual Life Res 1999;8:417-26.
37 Noordsy, Poster presented at: 154th APA Annual Meeting: 2001; New Orleans. USA.